Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single Center, Open Label, Randomized, Single-Dose, Three-Way Crossover Study to Compare the Pharmacokinetics and Bioavailability of Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex in Healthy Volunteers and to Collect Resistance Data During Application of NP101

NCT01381796 is registered in ClinicalTrials.gov with NuPathe Inc. as lead sponsor.

NCT NCT01381796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01381796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single Center, Open Label, Randomized, Single-Dose, Three-Way Crossover Study to Compare the Pharmacokinetics and Bioavailability of Two NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex in Healthy Volunteers and to Collect Resistance Data During Application of NP101
Lead sponsor
NuPathe Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2009
Completion date
September 30, 2010
Enrollment
63 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

compare bioequivalence patches previously used in the np101-007 study